Journal of acquired immune deficiency syndromes (1999)
Authors: Muiru AN, Bibangambah P, Hemphill L, Sentongo R, Kim JH, Triant VA, Bangsberg DR, Tsai AC, Martin JN, Haberer JE, Boum Y, Plutzky J, Hunt PW, Okello S, Siedner MJ
The lancet. HIV
Authors: Henrich TJ
Journal of pharmaceutical sciences
Authors: Deitchman AN, Singh RSP, Derendorf H
Circulation. Genomic and precision medicine
Authors: McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Authors: Fung M, Schwartz BS, Doernberg SB, Langelier C, Lo M, Graff L, Tan M, Logan AC, Chin-Hong P, Babik JM
The Journal of infectious diseases
Authors: Chen I, Diawara H, Mahamar A, Sanogo K, Keita S, Kone D, Diarra K, Djimde M, Keita M, Brown J, Roh ME, Hwang J, Pett H, Murphy M, Niemi M, Greenhouse B, Bousema T, Gosling R, Dicko A
The Journal of infectious diseases
Authors: Kelly JD, Barrie MB, Mesman AW, Karku S, Quiwa K, Drasher M, Schlough GW, Dierberg K, Koedoyoma S, Lindan CP, Jones JH, Chamie G, Worden L, Greenhouse B, Weiser SD, Porco TC, Rutherford GW, Richardson ET
AIDS (London, England) | Volume 32 of Issue 6
Authors: Carrico AW, Cherenack EM, Roach ME, Riley ED, Oni O, Dilworth SE, Shoptaw S, Hunt P, Roy S, Pallikkuth S, Pahwa S
OBJECTIVE
Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes.
DESIGN
Cross-sectional study at baseline for a randomized controlled trial.
METHODS
HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 T-cell count, interleukin-6, and alcohol use severity.
RESULTS
The sample of 84 virally suppressed MSM had a median CD4 T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05).
CONCLUSIONS
Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.
View on PubMed
BMC medical education
Authors: Peluso MJ, Luckett R, Mantzor S, Bedada AG, Saleeb P, Haverkamp M, Mosepele M, Haverkamp C, Maoto R, Prozesky D, Tapela N, Nkomazana O, Barak T
American journal of respiratory and critical care medicine
Authors: Ernst JD
